评价玻璃体内注射贝伐单抗（阿瓦斯汀）治疗糖尿病性黄斑水肿的疗效。

Evaluation of the Effect of Intravitreal Bevacizumab (Avastin) in Patients with Diabetic Macular Edema.

机构信息

Mechi Eye Hospital, Nepal.

出版信息

Nepal J Ophthalmol. 2020 Jul;12(24):236-244. doi: 10.3126/nepjoph.v12i2.28959.

DOI:10.3126/nepjoph.v12i2.28959

PMID:33978618

Abstract

INTRODUCTION

Diabetic macular edema (DME) is the leading cause of visual impairment in patients with diabetes mellitus. The objectives of the study was to figure out the effect of intravitreal injection bevacizumab on visual acuity and retinal thickness in people with DME.

MATERIALS AND METHODS

We observed the case records of patients with DME requiring injection Avastin (Genentech Inc., San Francisco, CA, USA) intravitreal from January to July 2016 in Mechi Eye Hospital. The eighty seven eyes of 60 patients with DME were included in the study. Inclusion criteria were determined independently of the age, metabolic control, type of diabetes mellitus, visual acuity, leakage area size,retinal thickness as measured by optical coherence tomography. All the patients were treated with 0.05 ml injection containing 1.25 mg of Avastin (Genentech Inc., San Francisco, CA, USA) after written informed consent.

RESULTS

The mean age group was 55.86 ± 9.61 years with 47 males and 13 females. At baseline the median BCVA was 1.00 (0.60-1.30) which improved to 0.78 (0.48- 1.00) at 6 weeks (p=0.001) which further improved to 0.78 (0.48-1.00) Log MAR (p value- 0.005) at 12 weeks and 0.60 (0.43- 1.00) Log MAR at 18 weeks (p value= 0.006). Baseline mean central macular thickness (CMT) on OCT was 436.24 ± 142.2μm which decreased to 387.74±130.98μm at 6 weeks, 346.82 ±116.79 μm at 12 weeks and 307.1 ±105.49μm. Changes in VA and decrease in central subfield macular thickness during follow up visit was statistically significant (p<0.05).

CONCLUSION

In this study, intravitreal injection Avastin resulted in improvement in VA and decrease in retinal thickness in patients with DME.

摘要

简介

糖尿病性黄斑水肿（DME）是糖尿病患者视力损害的主要原因。本研究的目的是探讨玻璃体内注射贝伐单抗对 DME 患者视力和视网膜厚度的影响。

材料和方法

我们观察了 2016 年 1 月至 7 月在美池眼科医院接受 Avastin（基因泰克公司，旧金山，加利福尼亚州，美国）玻璃体注射的 DME 患者的病历。本研究纳入了 60 例 87 只眼 DME 患者。纳入标准独立于年龄、代谢控制、糖尿病类型、视力、渗漏面积大小、光学相干断层扫描测量的视网膜厚度。所有患者均在知情同意后接受 0.05ml 含 1.25mgAvastin（基因泰克公司，旧金山，加利福尼亚州，美国）注射治疗。

结果

平均年龄组为 55.86 ± 9.61 岁，男性 47 例，女性 13 例。基线时 BCVA 中位数为 1.00（0.60-1.30），6 周时改善至 0.78（0.48-1.00）（p=0.001），12 周时进一步改善至 0.78（0.48-1.00）LogMAR（p 值-0.005），18 周时改善至 0.60（0.43-1.00）LogMAR（p 值=0.006）。OCT 上基线时平均中央黄斑厚度（CMT）为 436.24 ± 142.2μm，6 周时降至 387.74±130.98μm，12 周时降至 346.82 ±116.79μm，12 周时降至 307.1 ±105.49μm。随访期间视力和中心凹下黄斑厚度的变化具有统计学意义（p<0.05）。